HLS Therapeutics Inc represents values of integrity, innovation, and commitment to improving patients' lives. With a corporate philosophy focused on enhancing healthcare outcomes, they strive to develop and commercialize innovative therapies to address unmet medical needs. HLS Therapeutics Inc prioritizes patient safety, efficient operations, and collaboration with healthcare professionals to deliver high-quality treatments. By leveraging their expertise and building strategic partnerships, HLS Therapeutics Inc aims to create sustainable value for shareholders while making a positive impact on the healthcare industry.

HLS Therapeutics Inc is primarily present in Canada and the United States.

HLS Therapeutics Inc has achieved significant milestones in its development. Some of these key achievements include securing regulatory approvals for its leading pharmaceutical products, such as Vascepa® and Cortiment®. The company has also expanded its market presence through strategic partnerships, collaborations, and acquisitions. In addition, HLS Therapeutics Inc has demonstrated consistent revenue growth and achieved positive clinical trial results, reinforcing its position as an innovative player in the pharmaceutical industry. The company's commitment to advancing patient care and its strong product portfolio have contributed to its success in improving healthcare outcomes.

HLS Therapeutics Inc is a pharmaceutical company with a rich history and background. Established in (year), HLS Therapeutics has been dedicated to improving patient outcomes and enhancing quality of life. The company specializes in the development and commercialization of innovative therapies for various medical conditions. HLS Therapeutics has achieved significant milestones, such as (mention significant achievements or product launches), contributing to its reputation as a leader in the industry. With its unwavering commitment to research, development, and patient care, HLS Therapeutics continues to make strides in advancing healthcare solutions and remains at the forefront of the pharmaceutical sector.

The main competitors of HLS Therapeutics Inc in the market include companies like ABC Pharmaceuticals, XYZ Therapeutics, and DEF Health Sciences.

HLS Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of HLS Therapeutics Inc focuses on commercializing and acquiring innovative healthcare products and technologies. With a patient-centric approach, HLS Therapeutics aims to improve the lives of individuals by providing effective treatment options across different therapeutic areas. The company strategically identifies and partners with like-minded organizations, leveraging their expertise and market presence to drive growth. HLS Therapeutics emphasizes on marketing and promotion, ensuring wide accessibility to its products. By continuously assessing and expanding its product portfolio, HLS Therapeutics strives to deliver value to patients, healthcare professionals, and shareholders.

HLS Therapeutics KGV ir -4,56.

HLS Therapeutics KUV ir 1,42.

AlleAktien kvalitātes vērtējums HLS Therapeutics ir 1/10.

gaidāmā HLS Therapeutics apgrozījums ir 58,83 milj. USD.

gaidāmā HLS Therapeutics peļņa ir -18,32 milj. USD.

HLS Therapeutics Inc is a Canadian company specializing in the development and marketing of innovative products for rare diseases and chronic conditions. The company operates in two divisions: Medical Products and Specialty Pharmaceuticals. Its medical products include drugs for the treatment of cancer, autoimmune diseases, and rare diseases. HLS Therapeutics also develops biosimilars as cost-effective alternatives to expensive biologics. Its specialty pharmaceuticals focus on treating central nervous system disorders, including epilepsy and neuropathy, as well as cardiovascular diseases and cholesterol reduction. Some of its well-known products include Cortef for adrenal insufficiency treatment and Vascepa, an Omega-3 fatty acid ester for triglyceride reduction. The company's business model is based on researching and developing therapies for unmet medical needs and marketing them in North America and Europe. HLS Therapeutics collaborates closely with research and healthcare partners and has a high success rate in product approvals. It has an experienced leadership team and a strong network of physicians, scientists, and research institutions, allowing for continuous expansion of its innovative product pipeline. While prioritizing patient needs and delivering positive patient experiences, HLS Therapeutics follows a growth strategy through organic development, market expansion, strategic acquisitions, and partnerships. With its focus on meeting unmet medical needs, strong R&D capabilities, high-quality products, and innovative growth strategies, HLS Therapeutics is poised to remain a leader in the industry.

HLS Therapeutics izmaksā dividendes 0,20 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt HLS Therapeutics vai uzņēmums nedod dividendes.

HLS Therapeutics ISIN ir CA40390B1094.

HLS Therapeutics WKN ir A2JGH0.

HLS Therapeutics simbols ir HLS.TO.

Pēdējo 12 mēnešu laikā HLS Therapeutics maksāja dividendes 0,20 USD apmērā. Tas atbilst aptuveni 7,73 % dividendes ražībai. Nākamajos 12 mēnešos HLS Therapeutics plāno maksāt dividendes 0,20 USD apmērā.

HLS Therapeutics pašreizējā dividendu rentabilitāte ir 7,73 %.

HLS Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos augusts, novembris, februāris, maijs.

HLS Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,20 USD. Tas atbilst dividendes ražībai 7,33 %.

HLS Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu HLS Therapeutics apmērā 0,05 USD, kas tika izmaksāta 15.06.2023., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 27.04.2023..

Pēdējās dividendes izmaksa notika 15.06.2023..

Gadā 2023, HLS Therapeutics izmaksāja 0,2 USD dividendes.

HLS Therapeutics dividendes tiek izmaksātas USD.